biote Corp. (BTMD) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Financial metrics show improvement, with increased gross profit margin and reduced SG&A expenses, but cash reserves have decreased. The Q&A reveals concerns about clinic attrition and lack of clear improvement timelines. Despite positive restructuring efforts, tangible results are yet to manifest. The stock price impact is likely neutral as the market waits for clearer signs of recovery.
Key Financial Performance
Second quarter revenue Approximately flat at $48.9 million, reflecting an 8.4% decrease in procedure revenue that was partially offset by more than 30% sales growth in dietary supplements. The decrease in procedure revenue was due to slower growth rate of new clinic additions, higher-than-normal attrition of established clinics, and lower procedure volume. The increase in dietary supplement revenue was driven by growth in the e-commerce channel.
Dietary supplement revenue Increased 30.4% to $10.7 million, primarily driven by the growth of the e-commerce channel.
Gross profit margin 71.6%, a 280 basis point increase. The improvement was primarily due to cost savings from the continued vertical integration of the 503(B) manufacturing facility.
Selling, general and administrative (SG&A) expenses Decreased 12.2% to $24.2 million. The decrease was partly due to the timing of the annual marketing event, which shifted $2 million of SG&A spend to the third quarter, and temporarily lower expenses due to headcount adjustments.
Net income $3.9 million, inclusive of a $1.8 million loss due to the change in the fair value of the earn-out liabilities. This compares to a net loss of $10.4 million in the second quarter of 2024.
Diluted earnings per share $0.10 per share, compared to a diluted loss per share of $0.21 in the second quarter of 2024.
Adjusted EBITDA Increased 19.1% to $15.2 million with an adjusted EBITDA margin of 31.1%. This compares to adjusted EBITDA of $12.7 million and adjusted EBITDA margin of 25.9%. The increases were due to improved gross profit and lower operating expenses, including the timing shift of the annual provider event.
Second quarter cash flow from operations $7.1 million, contributing to $13.6 million for the first half of 2025.
Cash and cash equivalents $19.6 million as of June 30, 2025, compared to $41.7 million as of March 31, 2025. The reduction was due to payments for previously announced share repurchases related to the founder and affiliated parties.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Dietary Supplements: Revenue increased by 30.4% to $10.7 million, driven by growth in the e-commerce channel.
Hormone Replacement Therapy and Therapeutic Wellness: Focused on capturing a large and underpenetrated addressable market opportunity.
Strategic Organizational Restructuring: Implemented in May 2025 to drive sustainable growth, including changes to people, processes, and culture.
Sales Compensation Structure: Updated to align incentives with sales growth strategy, focusing on new clinic additions and revenue from the quick start program.
Sales Training Program: Expanded depth and implemented targeted strategies to align with a performance-based culture.
Operational Efficiency: Undertook a top-to-bottom review of core functions and internal processes to enhance efficiency and consistency.
Leadership Changes: Appointed Joey Lopes as Senior VP of Strategy and Commercial Operations to reaccelerate procedure growth and improve commercial productivity.
Financial Guidance Adjustment: Revised fiscal 2025 revenue guidance to above $190 million and adjusted EBITDA guidance to above $50 million due to stronger dietary supplement growth and weaker procedure revenue.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Procedure Revenue Decline: The company experienced an 8.4% decrease in procedure revenue, attributed to slower growth in new clinic additions, higher-than-normal attrition of established clinics, and lower procedure volume. Organizational changes and disruptions in clinical decision support software also contributed to this decline.
Organizational Restructuring Impact: The strategic reorganization, while aimed at long-term growth, has been disruptive to the business, particularly affecting procedure-related sales and causing short-term operational challenges.
Cash Flow Reduction: Cash and cash equivalents dropped significantly from $41.7 million to $19.6 million due to share repurchases, which could limit financial flexibility.
Revenue Guidance Adjustment: The company revised its fiscal 2025 revenue guidance downward, reflecting anticipated high single-digit declines in procedure revenue and slower-than-expected recovery in this segment.
Attrition of Established Clinics: Higher-than-normal attrition rates among established clinics are negatively impacting procedure revenue and overall business stability.
Dependence on Dietary Supplements: While dietary supplements showed strong growth, the company is increasingly reliant on this segment to offset declines in procedure revenue, which may not be sustainable long-term.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Fiscal 2025 Revenue Guidance: Biote has adjusted its fiscal 2025 revenue guidance to be above $190 million, reflecting a combination of procedure revenue declines and dietary supplement growth.
Fiscal 2025 Adjusted EBITDA Guidance: The company forecasts adjusted EBITDA to be above $50 million for fiscal 2025.
Procedure Revenue Trends: Procedure revenue is expected to decline by high single digits for the full year, with second-half trends similar to the second quarter.
Dietary Supplement Revenue Growth: Dietary supplement revenue is projected to grow at approximately a mid-teens percentage rate for fiscal 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
share repurchases: The reduction in cash and cash equivalents reflected payments for the previously announced share repurchases related to our founder and affiliated parties.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How far along is the verticalization process, and what percentage of pellets are being made there?
A:The verticalization process is currently in the low 40% to 50% penetration range. The company paused further progress to avoid disrupting commercial activities but plans to resume in Q3 to drive up penetration and improve margins.
Q:How much was the absolute number of procedures down in the quarter?
A:Management did not provide specific numbers but mentioned that the decline was volume-related, driven by clinic attrition, reduced volumes in existing clinics, and fewer new clinic starts. These issues began with the launch of CDSS in Q3 of the previous year and were compounded by a reorganization in May.
Q:What needs to happen for metrics like clinic attrition, new physician adds, and procedure volume to turn around?
A:Management believes the actions already taken, such as reorganization and new hires, will eventually bear fruit. However, they have not yet seen trends or upticks in volume to confirm this. They are optimistic about the long-term impact of these changes but cannot predict when metrics will improve.
Q:What is the time frame for key performance indicators (KPIs) to start improving?
A:Management stated it is too early to project a time frame for improvement. They are waiting to see trends in the right direction before making any predictions.
Q:What is driving the faster-than-expected attrition? Is it due to competition from GLP-1 adoption or internal factors?
A:Management stated that GLP-1 adoption is not impacting procedure revenue and views it as complementary to hormone replacement therapy. The primary drivers of attrition are internal factors, including disruptions from the CDSS launch and organizational restructuring.
Q:What are some of the longer-term initiatives in place?
A:Longer-term initiatives include improving the value proposition to customers to drive higher retention and attract new clinics. These initiatives aim to make the company's offerings more appealing and 'sticky' for customers.
Q:What is the biggest delta between performance and expectations for new clinic additions?
A:The slowdown in new starts, reduced volumes at existing clinics, and increased attrition were the main factors. Management highlighted that these headwinds were already discussed in previous quarters and are being addressed through both short-term and long-term initiatives.
Q:What are the biggest changes in the sales force and marketing strategy following the restructuring?
A:The sales force changes include a shift in focus from maintaining the business to driving growth, smaller territories, growth targets, and a new compensation plan aligned with growth. Leadership was consolidated for better accountability and messaging, and hiring, recruiting, and training processes were revamped.
Q:What tangible changes have been observed following the restructuring?
A:Management has not yet observed tangible changes but remains optimistic about the long-term benefits of the restructuring. They believe the changes will eventually lead to improved retention and growth.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for the absolute decline in procedures and did not project a time frame for when key performance indicators would improve. Their responses were qualitative and lacked detailed data or clarity in these areas.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Director
Commercial Insulet
Conference Instructions
Corp share
Cowen Research
Dietary supplement
Director Peterson
Division Jungwon
Division Kaitlyn
Division Leszek
Division Unidentified
ET day
Inc Research
Insulet expertise
Jefferies LLC
Jeffrey Wallin
Research Division
SGA
Securities Inc
adjustment
clinic addition
culture
decrease
energy
event
financials
market opportunity
objective
practitioner
procedure sale
program
reorganization
restructuring
sale compensation
sale supplement
share Corp
shift
shortfall
timing
BTMD Transcript
biote Corp. (BTMD) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call highlights several concerns: a significant decline in procedure revenue, gross profit margin, net income, and adjusted EBITDA. The recall and supply constraints have negatively impacted performance, with ongoing issues expected to affect Q2. Although management expresses confidence in future growth, the lack of specific metrics and continued inventory issues raise doubts. The Q&A session reveals analyst concerns about stabilization and supply constraints. Despite some positive signs, the overall sentiment is negative due to financial declines and uncertainties.
biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
Positive3-11
Biote's earnings call highlights strong financial performance with a 20% revenue increase and improved gross margins. Despite risks related to macroeconomic conditions and regulatory processes, the optimistic guidance for 2025 and strategic plans for growth, including sales team expansion and new product offerings, provide a positive outlook. The absence of negative Q&A feedback further supports a positive sentiment, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
biote Corp. (BTMD) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reveals several concerns: declining net income and adjusted EBITDA, high attrition rates, and procedural revenue decline. Although there's positive cash flow and growth in the supplements business, the lack of clear guidance on procedural growth and high attrition are worrying. The Q&A highlighted ongoing challenges with sales turnover and attrition, which could continue to pressure the stock. Overall, despite some positives, the negatives outweigh them, leading to a negative sentiment.
biote Corp. (BTMD) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call presents mixed signals. Financial metrics show improvement, with increased gross profit margin and reduced SG&A expenses, but cash reserves have decreased. The Q&A reveals concerns about clinic attrition and lack of clear improvement timelines. Despite positive restructuring efforts, tangible results are yet to manifest. The stock price impact is likely neutral as the market waits for clearer signs of recovery.
BTMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
